Compounding Pharmacists Must Use Disclaimer Under Settlement With Chiron
This article was originally published in The Pink Sheet Daily
Executive Summary
Tobi manufacturer Chiron sued the Respiratory Disease Network over promotion and compounding of tobramycin. Under the settlement, marketing materials for the pharmacy network's product must note that it has not been evaluated by FDA.